Stallergenes purchases Argentina\'s Alergo Pharma
Expands its presence in Latin America
French biopharmaceutical company Stallergenes, which is focused on developing allergen immunotherapy-based drugs, has expanded its business in Latin America with the purchase of Alergo Pharma, an Argentinian allergen immunotherapy (AIT) company.
Financial terms have not been disclosed.
The transaction combines two complementary allergen immunotherapy companies, which will work together to provide a more comprehensive and broader range of diagnosis and treatment solutions to patients suffering from allergic respiratory diseases.
The acquisition establishes Stallergenes among the top allergen immunotherapy pharmaceutical companies in Latin America, further broadening the company's geographic presence across the region.
'With its excellent market knowledge, an extensive distribution network and long-standing relationships with allergy specialists, Alergo Pharma is the leader in the AIT market in Argentina,' said Christian Chavy, Chief Executive of Stallergenes.
'This acquisition will significantly enhance Stallergenes' footprint in Latin America, and is consistent with our long-term strategy and commitment to fast-growing markets.'
